KIM
CLDI icon

Karpus Investment Management’s Calidi Biotherapeutics CLDI Stock Holding History

Karpus Investment Management’s Portfolio CLDI Stock Details CLDI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-202
Closed -$254K – 280
2023
Q2 		$254K Hold
202
– – 0.01% 296
2023
Q1 		$249K Hold
202
– – 0.01% 347
2022
Q4 		$246K Buy
+202
New +$242K 0.01% 401

Other funds holding CLDI

MC
Meteora Capital Boca Raton, Florida $1.36B AUM 21.19% 1-Year Est. Return
FC
Finepoint Capital Boston, Massachusetts $1.95B AUM 45.61% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SAMC
Spectrum Asset Management (California) Newport Beach, California $315M AUM 19.93% 1-Year Est. Return
RWI
Red Wave Investments Dillsburg, Pennsylvania $335M AUM 15.13% 1-Year Est. Return
DIM
Delta Investment Management San Francisco, California $559M AUM 19.86% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

Karpus Investment Management's CLDI Position: Q3 2023 in Review

Karpus Investment Management sold out of Calidi Biotherapeutics (CLDI) in Q3 2023, closing a stake of 202 shares — an estimated $254K sold.

Karpus Investment Management first reported a position in CLDI in Q4 2022 and held it in 3 quarters. The position peaked at $254K in Q2 2023. 12 funds tracked by Wall St. Rank hold CLDI as of Q3 2023.

  • Karpus Investment Management reported no remaining Calidi Biotherapeutics position as of Q3 2023 after selling out during the quarter.
  • Karpus Investment Management sold 202 Calidi Biotherapeutics shares in Q3 2023, an estimated $254K.
  • Karpus Investment Management first reported a position in Calidi Biotherapeutics in Q4 2022 and held it in 3 quarters.
  • Karpus Investment Management's Calidi Biotherapeutics position peaked at $254K in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2023.

Based on Karpus Investment Management's 13F filing for Q3 2023, filed 9 Nov 2023.